Janie J Yang1, Anusorn Thanataveerat2, Peter H R Green1, Benjamin Lebwohl3. 1. Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York. 2. Department of Biostatistics, Columbia University Mailman School of Public Health, New York, New York. 3. Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York. Electronic address: BL114@columbia.edu.
Abstract
BACKGROUND & AIMS: Some patients with refractory gastroesophageal reflux disease (GERD) actually have undiagnosed celiac disease. These patients often undergo an esophagogastroduodenoscopy (EGD) to determine the etiology and severity of GERD. Performing routine duodenal biopsy analysis during an EGD could identify patients with celiac disease. We evaluated the cost effectiveness of this approach. METHODS: We performed a systematic search of the MEDLINE database to identify publications through March 2014 on patients who underwent a duodenal biopsy analysis during an EGD for GERD. Data collected were used to construct a decision tree to calculate the cost effectiveness of an EGD with and without celiac disease tests. RESULTS: Among 10,000 patients with refractory GERD who underwent an EGD, we predicted a biopsy strategy would detect 70% of patients with celiac disease if the prevalence of celiac disease was 1% in this cohort. Biopsy analysis at the start of the EGD procedure would increase the remaining quality-adjusted life years (QALYs) by 0.0032, and increase the lifetime cost by $389/patient. Compared with no biopsy, the biopsy strategy cost $55,692.86/case of celiac disease detected, and $121,875/QALY gained. The incremental cost-effectiveness ratio for the biopsy strategy met the threshold of less than $50,000/QALY when 1 of the following parameters was met: when the utility of living with GERD was less than 0.88, when the prevalence of celiac disease in patients with refractory GERD was greater than 1.8%, when biopsy analysis detected celiac disease with more than 98.1% specificity, when the cost of a gluten-free diet was less than $645.85/y, or if the cost of proton pump inhibitor therapy was more than $5874.01/y. CONCLUSIONS: Based on base-case values, it is not cost effective to perform a biopsy analysis to detect celiac disease in patients undergoing an EGD for refractory GERD. However, the approach becomes cost effective when the prevalence of celiac disease in this population is 1.8% or greater.
BACKGROUND & AIMS: Some patients with refractory gastroesophageal reflux disease (GERD) actually have undiagnosed celiac disease. These patients often undergo an esophagogastroduodenoscopy (EGD) to determine the etiology and severity of GERD. Performing routine duodenal biopsy analysis during an EGD could identify patients with celiac disease. We evaluated the cost effectiveness of this approach. METHODS: We performed a systematic search of the MEDLINE database to identify publications through March 2014 on patients who underwent a duodenal biopsy analysis during an EGD for GERD. Data collected were used to construct a decision tree to calculate the cost effectiveness of an EGD with and without celiac disease tests. RESULTS: Among 10,000 patients with refractory GERD who underwent an EGD, we predicted a biopsy strategy would detect 70% of patients with celiac disease if the prevalence of celiac disease was 1% in this cohort. Biopsy analysis at the start of the EGD procedure would increase the remaining quality-adjusted life years (QALYs) by 0.0032, and increase the lifetime cost by $389/patient. Compared with no biopsy, the biopsy strategy cost $55,692.86/case of celiac disease detected, and $121,875/QALY gained. The incremental cost-effectiveness ratio for the biopsy strategy met the threshold of less than $50,000/QALY when 1 of the following parameters was met: when the utility of living with GERD was less than 0.88, when the prevalence of celiac disease in patients with refractory GERD was greater than 1.8%, when biopsy analysis detected celiac disease with more than 98.1% specificity, when the cost of a gluten-free diet was less than $645.85/y, or if the cost of proton pump inhibitor therapy was more than $5874.01/y. CONCLUSIONS: Based on base-case values, it is not cost effective to perform a biopsy analysis to detect celiac disease in patients undergoing an EGD for refractory GERD. However, the approach becomes cost effective when the prevalence of celiac disease in this population is 1.8% or greater.
Authors: Peter D Mooney; Simon H Wong; Alexander J Johnston; Matthew Kurien; Anastasios Avgerinos; David S Sanders Journal: Clin Gastroenterol Hepatol Date: 2015-01-26 Impact factor: 11.382
Authors: David S Sanders; Andrew D Hopper; Iman A F Azmy; Nahida Rahman; David P Hurlstone; John S Leeds; Rina R George; Neeraj Bhala Journal: Ann Surg Date: 2005-08 Impact factor: 12.969
Authors: Kent D Katz; Shahrooz Rashtak; Brian D Lahr; L Joseph Melton; Patricia K Krause; Kristine Maggi; Nicholas J Talley; Joseph A Murray Journal: Am J Gastroenterol Date: 2011-03-01 Impact factor: 10.864
Authors: Giovanni Cammarota; Giuseppe A Pirozzi; Antonio Martino; Giuseppe Zuccalà; Rossella Cianci; Lucio Cuoco; Veronica Ojetti; Matteo Landriscina; Massimo Montalto; Fabio M Vecchio; Giovanni Gasbarrini; Antonio Gasbarrini Journal: Gastrointest Endosc Date: 2004-08 Impact factor: 9.427
Authors: Jessica R Biesiekierski; Evan D Newnham; Susan J Shepherd; Jane G Muir; Peter R Gibson Journal: Nutr Clin Pract Date: 2014-04-16 Impact factor: 3.080
Authors: C Hallert; C Grännö; C Grant; S Hultén; G Midhagen; M Ström; H Svensson; T Valdimarsson; T Wickström Journal: Scand J Gastroenterol Date: 1998-09 Impact factor: 2.423